Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Charles Daley

Concepts (471)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Mycobacterium Infections, Nontuberculous
100
2026
339
18.150
Why?
Mycobacterium avium-intracellulare Infection
29
2026
63
9.530
Why?
Mycobacterium abscessus
43
2026
110
9.150
Why?
Mycobacterium avium Complex
44
2026
87
8.580
Why?
Nontuberculous Mycobacteria
54
2026
189
7.890
Why?
Lung Diseases
47
2026
780
7.730
Why?
Anti-Bacterial Agents
69
2026
1922
6.500
Why?
Antitubercular Agents
39
2025
208
5.270
Why?
Tuberculosis
33
2025
283
4.890
Why?
Tuberculosis, Pulmonary
26
2025
127
4.350
Why?
Tuberculosis, Multidrug-Resistant
14
2025
47
3.440
Why?
Amikacin
19
2026
29
3.410
Why?
Mycobacterium Infections
12
2019
55
3.160
Why?
Mycobacterium
16
2026
101
2.920
Why?
Mycobacterium kansasii
10
2020
14
2.850
Why?
Bronchiectasis
19
2026
112
2.780
Why?
Cystic Fibrosis
22
2025
1160
2.620
Why?
Mycobacterium tuberculosis
28
2025
318
2.610
Why?
Macrolides
15
2023
67
2.250
Why?
Interferon-gamma Release Tests
7
2025
32
1.990
Why?
Drug Resistance, Bacterial
21
2023
185
1.860
Why?
Microbial Sensitivity Tests
29
2026
363
1.690
Why?
Sputum
25
2020
302
1.520
Why?
Disease Outbreaks
7
2025
419
1.390
Why?
Humans
205
2026
145140
1.300
Why?
Latent Tuberculosis
8
2017
70
1.200
Why?
Pneumonia, Bacterial
6
2017
113
1.170
Why?
Drug Therapy, Combination
22
2026
1043
1.130
Why?
AIDS-Related Opportunistic Infections
4
2016
130
1.100
Why?
Boron Compounds
2
2026
29
1.100
Why?
Antibiotics, Antitubercular
9
2021
35
1.050
Why?
Clofazimine
4
2021
15
1.050
Why?
Rifampin
14
2024
79
1.040
Why?
Ethambutol
11
2026
27
1.010
Why?
Clarithromycin
14
2026
24
0.960
Why?
Pneumonia
5
2023
635
0.950
Why?
Tetracyclines
1
2025
16
0.920
Why?
Patient Reported Outcome Measures
2
2026
497
0.840
Why?
Treatment Outcome
35
2026
11741
0.830
Why?
Oxazolidinones
3
2013
17
0.820
Why?
Acetamides
3
2013
39
0.800
Why?
HIV Infections
15
2022
3186
0.770
Why?
Global Health
8
2018
403
0.770
Why?
Fatigue
1
2025
363
0.770
Why?
Aged
57
2026
26096
0.760
Why?
Tuberculin Test
6
2016
36
0.720
Why?
Equipment Contamination
2
2019
67
0.690
Why?
Azithromycin
7
2026
101
0.680
Why?
Middle Aged
64
2026
36126
0.680
Why?
Professional Practice Gaps
1
2020
15
0.640
Why?
Imipenem
7
2024
16
0.620
Why?
beta-Lactams
3
2026
32
0.620
Why?
Adult
57
2026
40665
0.610
Why?
Disease Management
4
2021
651
0.600
Why?
Female
82
2026
78636
0.590
Why?
Male
82
2026
72664
0.590
Why?
San Francisco
10
2014
60
0.560
Why?
Practice Guidelines as Topic
9
2026
1579
0.550
Why?
Molecular Epidemiology
4
2006
73
0.550
Why?
Administration, Inhalation
7
2026
571
0.510
Why?
Algorithms
1
2025
1845
0.500
Why?
Health Care Sector
2
2013
26
0.480
Why?
Linezolid
5
2026
25
0.480
Why?
Recurrence
11
2025
1134
0.480
Why?
Extensively Drug-Resistant Tuberculosis
2
2013
6
0.470
Why?
beta-Lactamase Inhibitors
6
2026
9
0.470
Why?
Drug Resistance, Multiple, Bacterial
4
2019
77
0.470
Why?
Nebramycin
2
2025
2
0.460
Why?
United States
32
2025
16065
0.460
Why?
Phylogeny
5
2021
917
0.460
Why?
Genome, Bacterial
5
2021
123
0.450
Why?
Lung
16
2024
4101
0.450
Why?
World Health Organization
3
2024
104
0.440
Why?
Retrospective Studies
29
2025
17247
0.420
Why?
Organ Transplantation
2
2024
250
0.410
Why?
Drug Synergism
4
2024
354
0.400
Why?
Communicable Disease Control
1
2014
85
0.390
Why?
Sex Factors
1
2019
2099
0.390
Why?
Serologic Tests
1
2012
54
0.370
Why?
Quality of Life
8
2026
3194
0.360
Why?
Professional Practice
1
2012
57
0.360
Why?
Rifabutin
2
2012
7
0.350
Why?
Opportunistic Infections
1
2011
47
0.340
Why?
Pyrazinamide
4
2021
16
0.340
Why?
Antibiotic Prophylaxis
1
2012
134
0.340
Why?
Liposomes
2
2026
259
0.330
Why?
Cefoxitin
4
2026
8
0.320
Why?
Drug Administration Schedule
8
2025
781
0.320
Why?
Occupational Health
1
2013
211
0.310
Why?
Aged, 80 and over
15
2025
8318
0.300
Why?
Occupational Exposure
1
2013
355
0.290
Why?
Cross Infection
2
2025
260
0.290
Why?
Disease Progression
8
2026
2857
0.290
Why?
Diarylquinolines
3
2025
16
0.280
Why?
Incidence
10
2019
2915
0.280
Why?
Mass Screening
3
2016
1354
0.280
Why?
Cardiac Surgical Procedures
3
2019
608
0.270
Why?
Dose-Response Relationship, Drug
6
2026
2026
0.270
Why?
Double-Blind Method
5
2026
2057
0.260
Why?
Directly Observed Therapy
2
2005
15
0.260
Why?
Antigens, Bacterial
5
2012
126
0.260
Why?
Europe
3
2025
416
0.260
Why?
Cefuroxime
2
2024
5
0.260
Why?
Carcinoma, Squamous Cell
1
2012
640
0.260
Why?
Prospective Studies
16
2025
8035
0.260
Why?
Tuberculosis, Pleural
2
2003
7
0.250
Why?
Health Personnel
3
2014
749
0.250
Why?
Treatment Failure
5
2026
360
0.240
Why?
Cephalosporins
2
2024
45
0.240
Why?
Morbidity
2
2019
322
0.240
Why?
Tomography, X-Ray Computed
9
2020
2767
0.240
Why?
Suspensions
1
2026
28
0.240
Why?
Genomics
4
2021
819
0.230
Why?
Administration, Oral
4
2025
862
0.220
Why?
Phage Therapy
1
2025
17
0.220
Why?
ROC Curve
4
2020
617
0.220
Why?
Diagnostic Tests, Routine
2
2019
107
0.220
Why?
Antibodies, Monoclonal
1
2012
1505
0.220
Why?
Oxazepines
2
2025
5
0.220
Why?
Benzoxazoles
2
2025
20
0.220
Why?
Peptidyl Transferases
2
2024
8
0.220
Why?
Mutation
5
2019
4071
0.220
Why?
Dipeptidyl-Peptidase IV Inhibitors
1
2025
46
0.220
Why?
Disease Transmission, Infectious
1
2005
69
0.210
Why?
Water Microbiology
1
2005
84
0.210
Why?
DNA Fingerprinting
1
2004
28
0.210
Why?
Contact Tracing
1
2004
26
0.210
Why?
Arizona
1
2024
80
0.210
Why?
Boronic Acids
1
2024
36
0.210
Why?
Alveolitis, Extrinsic Allergic
1
2005
93
0.200
Why?
Research
2
2018
430
0.200
Why?
Adolescent
19
2025
22479
0.200
Why?
DNA, Bacterial
3
2021
320
0.200
Why?
Self Administration
1
2004
122
0.200
Why?
Risk Factors
9
2019
10857
0.200
Why?
Medical Tourism
1
2023
9
0.200
Why?
Mexico
1
2024
232
0.200
Why?
Time Factors
8
2026
7107
0.200
Why?
Biomedical Research
5
2020
717
0.200
Why?
Colorado
5
2024
4538
0.190
Why?
London
1
2023
46
0.190
Why?
Biomarkers
3
2020
4282
0.190
Why?
Leprostatic Agents
1
2022
6
0.190
Why?
Stem Cell Transplantation
1
2024
189
0.190
Why?
Clinical Trials as Topic
5
2026
1058
0.190
Why?
Republic of Korea
6
2019
43
0.190
Why?
Young Adult
12
2025
14176
0.180
Why?
Forced Expiratory Volume
6
2025
450
0.180
Why?
Pneumonectomy
2
2016
167
0.180
Why?
Meningitis
1
2023
80
0.180
Why?
Registries
5
2020
2401
0.180
Why?
Spectinomycin
1
2021
2
0.180
Why?
Isoniazid
4
2019
70
0.180
Why?
Thorax
1
2022
51
0.170
Why?
Lung Neoplasms
2
2012
2662
0.170
Why?
Radiography, Thoracic
3
2017
172
0.170
Why?
Reproducibility of Results
3
2025
3410
0.170
Why?
Psychometrics
1
2025
731
0.170
Why?
Comorbidity
4
2019
1657
0.170
Why?
Cohort Studies
8
2020
5988
0.160
Why?
Safety
1
2003
357
0.160
Why?
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
1
2020
6
0.160
Why?
Sensitivity and Specificity
5
2025
1995
0.160
Why?
Cluster Analysis
4
2020
500
0.160
Why?
Respiratory Therapy
1
2020
25
0.160
Why?
Serine Proteases
1
2020
26
0.160
Why?
Bacteriophages
1
2022
110
0.160
Why?
Prevalence
4
2019
2855
0.150
Why?
Child
13
2025
22670
0.150
Why?
Area Under Curve
3
2020
329
0.150
Why?
Nitroimidazoles
1
2019
16
0.150
Why?
Mycobacterium fortuitum
1
2019
2
0.150
Why?
Follow-Up Studies
5
2020
5411
0.150
Why?
Oxazoles
1
2019
48
0.150
Why?
Durable Medical Equipment
1
2019
5
0.150
Why?
Genotyping Techniques
1
2019
71
0.150
Why?
Bronchoscopy
1
2020
227
0.150
Why?
Cost of Illness
1
2021
324
0.140
Why?
Surveys and Questionnaires
2
2025
6055
0.140
Why?
Genotype
6
2019
1844
0.140
Why?
Drug-Related Side Effects and Adverse Reactions
1
2021
261
0.140
Why?
Patient Selection
1
2003
733
0.140
Why?
DNA Gyrase
1
2018
8
0.140
Why?
Azabicyclo Compounds
3
2024
7
0.140
Why?
Aza Compounds
2
2010
12
0.140
Why?
Respiratory System Agents
1
2018
22
0.140
Why?
Internationality
1
2019
156
0.140
Why?
Hospitals
1
2023
732
0.140
Why?
Disease Models, Animal
3
2025
4552
0.130
Why?
Tertiary Care Centers
1
2019
195
0.130
Why?
Patient Compliance
3
2011
587
0.130
Why?
Musculoskeletal Diseases
1
2019
90
0.130
Why?
Tuberculosis Vaccines
2
2010
4
0.130
Why?
Anti-HIV Agents
3
2016
908
0.130
Why?
Hematopoietic Stem Cell Transplantation
1
2024
698
0.130
Why?
alpha 1-Antitrypsin Deficiency
1
2018
61
0.130
Why?
Pulmonary Medicine
1
2018
78
0.130
Why?
Biological Specimen Banks
1
2018
103
0.130
Why?
Salvage Therapy
1
2018
165
0.130
Why?
Elephants
1
2017
7
0.130
Why?
Interferon-gamma
4
2007
784
0.130
Why?
Agammaglobulinemia
1
2017
36
0.130
Why?
Fluoroquinolones
3
2018
44
0.130
Why?
Databases, Genetic
1
2018
238
0.130
Why?
Surgical Equipment
1
2016
8
0.120
Why?
Quinolines
2
2010
190
0.120
Why?
Kartagener Syndrome
1
2016
31
0.120
Why?
Staphylococcal Infections
2
2018
390
0.120
Why?
Immunologic Deficiency Syndromes
1
2016
65
0.120
Why?
Prognosis
5
2020
4310
0.120
Why?
Genes, Bacterial
1
2016
152
0.120
Why?
Levofloxacin
1
2016
21
0.120
Why?
Adrenal Cortex Hormones
1
2019
483
0.120
Why?
Cough
3
2023
123
0.110
Why?
Public Health
4
2016
571
0.110
Why?
Gene Expression Regulation
2
2020
2588
0.110
Why?
Surgical Wound Infection
1
2019
329
0.110
Why?
Patient Outcome Assessment
1
2016
130
0.110
Why?
Gene Expression Profiling
2
2020
1763
0.110
Why?
Chronic Disease
3
2023
1806
0.110
Why?
Drug Tolerance
1
2015
99
0.110
Why?
Guidelines as Topic
1
2016
266
0.110
Why?
Sequence Analysis, DNA
2
2014
776
0.100
Why?
Drug Evaluation, Preclinical
2
2026
196
0.100
Why?
Antiretroviral Therapy, Highly Active
2
2007
279
0.100
Why?
DNA Transposable Elements
2
2006
124
0.100
Why?
Genetic Variation
2
2021
967
0.100
Why?
Peptidoglycan
2
2026
28
0.100
Why?
beta-Lactamases
2
2026
53
0.100
Why?
CD4 Lymphocyte Count
2
2004
280
0.100
Why?
MicroRNAs
1
2020
686
0.100
Why?
Anti-Inflammatory Agents
1
2017
477
0.100
Why?
Computational Biology
1
2018
669
0.100
Why?
Patient Acceptance of Health Care
2
2018
881
0.100
Why?
Societies, Medical
4
2020
898
0.100
Why?
Patient-Centered Care
1
2018
547
0.100
Why?
Glucocorticoids
1
2017
531
0.090
Why?
Contraindications
1
2012
90
0.090
Why?
Gene Expression Regulation, Bacterial
1
2015
337
0.090
Why?
Immunoenzyme Techniques
1
2012
200
0.090
Why?
Transcriptome
2
2015
1029
0.090
Why?
Glycolipids
1
2012
53
0.090
Why?
Models, Statistical
1
2016
671
0.090
Why?
Cytokines
2
2011
2048
0.090
Why?
Antibodies, Bacterial
1
2012
147
0.090
Why?
Randomized Controlled Trials as Topic
1
2018
1742
0.090
Why?
Drug Resistance, Multiple
1
2011
25
0.090
Why?
Chemical and Drug Induced Liver Injury
2
2003
138
0.080
Why?
Immunoglobulin A
1
2012
214
0.080
Why?
Drug Interactions
1
2012
404
0.080
Why?
Pulmonary Disease, Chronic Obstructive
2
2018
919
0.080
Why?
Debridement
1
2011
85
0.080
Why?
Kaplan-Meier Estimate
3
2019
968
0.080
Why?
Virulence
1
2011
278
0.080
Why?
Metagenomics
2
2021
149
0.080
Why?
Hospitals, General
2
2014
25
0.080
Why?
Animals
8
2025
37952
0.080
Why?
Respiratory Tract Infections
1
2014
394
0.080
Why?
Case-Control Studies
3
2020
3616
0.080
Why?
Hepatitis, Viral, Human
1
2009
21
0.080
Why?
Netherlands
2
2012
82
0.070
Why?
Mice
5
2025
18303
0.070
Why?
Bacteriological Techniques
1
2009
66
0.070
Why?
Confidence Intervals
2
2015
330
0.070
Why?
Forkhead Transcription Factors
2
2007
207
0.070
Why?
Interleukins
2
2007
248
0.070
Why?
Clinical Decision-Making
2
2026
362
0.070
Why?
Lung Transplantation
1
2012
329
0.070
Why?
Vitamins
1
2010
182
0.070
Why?
Early Diagnosis
1
2009
251
0.070
Why?
Proportional Hazards Models
2
2019
1325
0.070
Why?
Radiography
2
2008
852
0.070
Why?
RNA, Ribosomal, 23S
2
2018
12
0.070
Why?
Interleukin-9
1
2007
11
0.070
Why?
Child, Preschool
4
2016
11835
0.070
Why?
Logistic Models
3
2019
2133
0.070
Why?
Hospitalization
1
2018
2458
0.070
Why?
Survival Analysis
2
2016
1371
0.070
Why?
Reagent Kits, Diagnostic
1
2007
33
0.060
Why?
Interleukin-12 Subunit p40
1
2007
9
0.060
Why?
Polysaccharides, Bacterial
1
2007
69
0.060
Why?
Pneumonia, Pneumococcal
1
2007
47
0.060
Why?
Congresses as Topic
2
2020
223
0.060
Why?
Th1 Cells
1
2007
139
0.060
Why?
Polymorphism, Single Nucleotide
3
2021
2136
0.060
Why?
Vitamin D
1
2010
403
0.060
Why?
Survivors
1
2010
522
0.060
Why?
Liver Function Tests
2
2003
105
0.060
Why?
Interleukin-8
1
2007
269
0.060
Why?
Age Factors
3
2019
3338
0.060
Why?
Japan
1
2026
148
0.060
Why?
Monte Carlo Method
1
2026
147
0.060
Why?
Keratosis
1
2025
16
0.060
Why?
Regression Analysis
1
2008
998
0.060
Why?
Hydrotherapy
1
2005
7
0.060
Why?
Penicillin-Binding Proteins
1
2024
2
0.060
Why?
Bacterial Load
1
2025
67
0.050
Why?
Immunosuppressive Agents
1
2009
837
0.050
Why?
Microbial Viability
1
2025
83
0.050
Why?
Coinfection
2
2018
143
0.050
Why?
Antirheumatic Agents
1
2007
307
0.050
Why?
Anti-Retroviral Agents
1
2007
251
0.050
Why?
Whole Genome Sequencing
1
2025
177
0.050
Why?
Cost-Benefit Analysis
2
2024
640
0.050
Why?
Biopsy
2
2005
1079
0.050
Why?
Mycobacterium xenopi
2
2014
2
0.050
Why?
Respiratory Function Tests
2
2016
543
0.050
Why?
Streptomycin
1
2003
18
0.050
Why?
Delphi Technique
1
2026
330
0.050
Why?
Molecular Docking Simulation
1
2024
119
0.050
Why?
Carrier State
1
2004
78
0.050
Why?
Influenza, Human
1
2009
624
0.050
Why?
Dust
1
2023
92
0.050
Why?
Multicenter Studies as Topic
1
2025
410
0.050
Why?
Pseudomonas Infections
2
2016
230
0.050
Why?
Staphylococcus aureus
2
2018
451
0.050
Why?
Medicare
2
2019
902
0.050
Why?
Substance Abuse, Intravenous
1
2004
127
0.050
Why?
Tumor Necrosis Factor-alpha
1
2007
1216
0.050
Why?
Homosexuality, Male
1
2004
231
0.050
Why?
Predictive Value of Tests
2
2007
2115
0.050
Why?
Databases, Factual
2
2019
1488
0.050
Why?
Transplant Recipients
1
2024
180
0.040
Why?
Los Angeles
1
2002
73
0.040
Why?
Survival Rate
1
2007
2087
0.040
Why?
Lactams
1
2021
28
0.040
Why?
Drug Costs
1
2003
117
0.040
Why?
Amoxicillin
1
2022
35
0.040
Why?
Cross-Sectional Studies
3
2025
5886
0.040
Why?
Phenotype
2
2021
3138
0.040
Why?
Clone Cells
1
2021
263
0.040
Why?
Bacterial Proteins
1
2007
962
0.040
Why?
Carboxypeptidases
1
2020
12
0.040
Why?
Real-Time Polymerase Chain Reaction
1
2021
337
0.040
Why?
Water
1
2023
445
0.040
Why?
Leukocyte Elastase
1
2020
74
0.040
Why?
Gene Ontology
1
2020
53
0.040
Why?
Ambulatory Care
1
2005
608
0.040
Why?
Multivariate Analysis
1
2003
1546
0.040
Why?
Chimera
1
2019
60
0.040
Why?
Medication Adherence
1
2024
540
0.040
Why?
United States Food and Drug Administration
1
2020
207
0.040
Why?
Neutrophils
1
2025
1123
0.040
Why?
Public Health Surveillance
1
2019
83
0.040
Why?
Stem Cells
1
2023
624
0.040
Why?
Meat
1
2019
64
0.040
Why?
Cross-Over Studies
1
2021
608
0.040
Why?
Mice, Inbred BALB C
1
2021
1261
0.040
Why?
Molecular Diagnostic Techniques
1
2019
103
0.040
Why?
Population Surveillance
1
2002
484
0.030
Why?
Risk Assessment
2
2019
3740
0.030
Why?
Ribosomal Proteins
1
2018
93
0.030
Why?
Prosthesis-Related Infections
1
2019
98
0.030
Why?
Insurance Claim Review
1
2018
83
0.030
Why?
Symptom Assessment
1
2019
136
0.030
Why?
Gene Expression
2
2016
1474
0.030
Why?
Enzyme-Linked Immunosorbent Assay
2
2011
847
0.030
Why?
International Cooperation
1
2018
197
0.030
Why?
Gene Regulatory Networks
1
2020
317
0.030
Why?
Animals, Zoo
1
2017
15
0.030
Why?
Drug Monitoring
2
2016
399
0.030
Why?
Methyltransferases
1
2017
75
0.030
Why?
Otitis
1
2016
9
0.030
Why?
Pseudomonas
1
2016
30
0.030
Why?
Drug Resistance, Microbial
1
2016
64
0.030
Why?
Delivery of Health Care
1
2023
946
0.030
Why?
Immunoglobulins
1
2017
161
0.030
Why?
Micronesia
1
2016
7
0.030
Why?
Mycobacterium chelonae
1
2016
8
0.030
Why?
Spirometry
1
2016
233
0.030
Why?
Host-Pathogen Interactions
1
2019
361
0.030
Why?
Multiple Pulmonary Nodules
1
2016
23
0.030
Why?
Vital Capacity
1
2016
292
0.030
Why?
Injections, Intravenous
1
2016
197
0.030
Why?
Body Temperature Regulation
1
2016
105
0.030
Why?
Needs Assessment
1
2018
401
0.030
Why?
Bronchi
1
2017
263
0.030
Why?
Drug Combinations
1
2016
396
0.030
Why?
Uganda
1
2015
89
0.030
Why?
Leukocytes, Mononuclear
2
2007
573
0.030
Why?
Rhinitis
1
2016
169
0.030
Why?
Fibrosis
1
2017
554
0.030
Why?
Gastroesophageal Reflux
1
2016
236
0.030
Why?
Research Design
1
2020
1132
0.030
Why?
Sinusitis
1
2016
227
0.030
Why?
Insurance, Health
1
2016
310
0.030
Why?
Sequence Homology, Nucleic Acid
1
2013
156
0.030
Why?
RNA, Messenger
2
2015
2803
0.020
Why?
False Positive Reactions
1
2014
123
0.020
Why?
Consensus
1
2016
478
0.020
Why?
Mycobacterium avium
1
2013
21
0.020
Why?
DNA, Ribosomal Spacer
1
2012
7
0.020
Why?
Mycolic Acids
1
2012
6
0.020
Why?
Greece
1
2012
9
0.020
Why?
Geography
1
2013
185
0.020
Why?
Bacterial Typing Techniques
1
2012
40
0.020
Why?
Self Report
1
2017
867
0.020
Why?
Iran
1
2012
44
0.020
Why?
Italy
1
2012
114
0.020
Why?
Sweden
1
2012
113
0.020
Why?
DNA-Directed RNA Polymerases
1
2012
62
0.020
Why?
Cerebrospinal Fluid
1
2012
88
0.020
Why?
Species Specificity
1
2013
545
0.020
Why?
Developing Countries
2
2005
316
0.020
Why?
Heat-Shock Proteins
1
2012
139
0.020
Why?
Protein Array Analysis
1
2011
56
0.020
Why?
Microspheres
1
2011
141
0.020
Why?
Drug Discovery
1
2012
153
0.020
Why?
Bone Marrow Cells
1
2012
320
0.020
Why?
Demography
1
2011
282
0.020
Why?
Adaptation, Physiological
1
2015
560
0.020
Why?
Pseudomonas aeruginosa
1
2014
395
0.020
Why?
In Vitro Techniques
1
2012
1048
0.020
Why?
Evolution, Molecular
1
2014
490
0.020
Why?
Body Mass Index
1
2019
2437
0.020
Why?
Postoperative Care
1
2012
286
0.020
Why?
RNA, Ribosomal, 16S
1
2012
507
0.020
Why?
Referral and Consultation
1
2016
862
0.020
Why?
Hepatitis, Chronic
1
2009
5
0.020
Why?
Smoking
1
2016
1470
0.020
Why?
Preoperative Care
1
2012
380
0.020
Why?
Age Distribution
1
2010
402
0.020
Why?
Sex Distribution
1
2010
386
0.020
Why?
Pleural Diseases
1
2009
23
0.020
Why?
Fatty Acids
1
2012
457
0.020
Why?
Anxiety
1
2016
1117
0.020
Why?
Transcription, Genetic
1
2015
1454
0.020
Why?
Age of Onset
1
2010
554
0.020
Why?
Vulnerable Populations
1
2009
175
0.020
Why?
Molecular Sequence Data
1
2012
2881
0.020
Why?
False Negative Reactions
1
2007
61
0.020
Why?
Lymphatic Diseases
1
2007
21
0.020
Why?
Urinalysis
1
2007
83
0.020
Why?
Continuity of Patient Care
1
2009
296
0.020
Why?
Depression
1
2016
1537
0.020
Why?
Bone Diseases
1
2007
61
0.020
Why?
Forced Expiratory Flow Rates
1
2006
10
0.010
Why?
Clinical Laboratory Techniques
1
2007
96
0.010
Why?
Cystic Fibrosis Transmembrane Conductance Regulator
1
2010
371
0.010
Why?
Longitudinal Studies
1
2014
2949
0.010
Why?
Africa
1
2006
118
0.010
Why?
Lung Diseases, Interstitial
1
2012
659
0.010
Why?
Infection Control
1
2007
173
0.010
Why?
Skin Diseases
1
2007
152
0.010
Why?
C-Reactive Protein
1
2007
422
0.010
Why?
Asthma
1
2016
1795
0.010
Why?
India
1
2005
213
0.010
Why?
Up-Regulation
1
2007
846
0.010
Why?
Virus Latency
1
2005
90
0.010
Why?
Anti-Infective Agents
1
2007
232
0.010
Why?
Dendritic Cells
1
2007
496
0.010
Why?
Quality of Health Care
1
2009
692
0.010
Why?
Wounds and Injuries
1
2012
960
0.010
Why?
Cost Savings
1
2004
86
0.010
Why?
Diagnostic Techniques, Respiratory System
1
2003
5
0.010
Why?
Pleura
1
2003
28
0.010
Why?
HIV Seronegativity
1
2003
29
0.010
Why?
Costs and Cost Analysis
1
2004
221
0.010
Why?
Pleural Effusion
1
2003
59
0.010
Why?
HIV Seropositivity
1
2003
119
0.010
Why?
Severity of Illness Index
1
2010
2928
0.010
Why?
Chi-Square Distribution
1
2003
527
0.010
Why?
Infant
1
2016
10060
0.010
Why?
Clinical Protocols
1
2003
280
0.010
Why?
Mice, Inbred C57BL
1
2012
5972
0.010
Why?
Data Interpretation, Statistical
1
2003
368
0.010
Why?
Health Policy
1
2004
400
0.010
Why?
Models, Theoretical
1
2004
556
0.010
Why?
Hypertension, Pulmonary
1
2012
1955
0.010
Why?
Rural Population
1
2005
657
0.010
Why?
Liver
1
2002
1893
0.010
Why?
Daley's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)